Mezzanine and Stockholders’ Equity
|3 Months Ended|
Mar. 31, 2018
|Stockholders' Equity Note [Abstract]|
All the historical NMM share and per share information has been adjusted to reflect the exchange ratio from the Merger (see Note 3).
As the redemption feature (see Note 2) of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interests in mezzanine or temporary equity.
As of the date of this Quarterly Report on Form 10-Q, 1,000,970 shares, which are net of 3,039,749 holdback shares and are subject to ApolloMed receiving from those former NMM shareholders a properly completed letter of transmittal (and related exhibits) before such former NMM shareholders may receive their pro rata portion of ApolloMed common stock and warrants. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The condensed consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares on the Effective Date of the Merger.
On March 21, 2018, the Company issued 37,593 shares of the Company’s common stock to the Company’s Chief Operating Officer for prior services rendered. The stock price on the date of issuance was $16.80, which resulted in the Company recording $631,562 of share-based compensation expense.
See options and warrants section below for common stock issued upon exercise of stock options and stock purchase warrants.
The Company’s outstanding stock options consisted of the following:
During the quarter ended March 31, 2018, stock options were exercised pursuant to the cashless exercise provision of the option agreement, with respect to 54,536 shares of the Company’s common stock, which resulted in the Company issuing 43,201 net shares.
During the quarter ended March 31, 2018, stock options were exercised for 75,000 shares of the Company’s common stock, which resulted in proceeds of approximately $479,000. The exercise price ranged from $2.10 to $10.00 per share.
Outstanding stock options granted to primary care physicians to purchase shares of APC’s common stock consisted of the following:
The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of common stock as of March 31, 2018.
Share-based compensation expense related to option awards granted to primary care physicians to purchase shares of APC’s common stock, recognized over their respective vesting periods, consisted of the following:
The remaining unrecognized share-based compensation expense of stock option awards granted to primary care physicians to purchase shares of APC’s common stock as of March 31, 2018 was $1,214,292, which is expected to be recognized over the remaining term of 1.50 years.
The Company’s outstanding warrants consisted of the following:
During the quarter ended March 31, 2018, common stock warrants were exercised for 191,625 shares of the Company’s common stock, which resulted in proceeds of approximately $1.4 million. The exercise price ranged from $4.00 to $10.00 per share.
APC owns 1,682,110 shares of ApolloMed’s common stock as of March 31, 2018, which are legally issued and outstanding but excluded from shares of common stock outstanding in the condensed consolidated financial statements, as such shares are treated as treasury shares for accounting purposes.
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
Reference 1: http://www.xbrl.org/2003/role/presentationRef